- 1 **Title**: Post-peak mpox in England: epidemiology, reinfection, and vaccine effectiveness –
- 2 data from 2023
- 3 **Authors**: Hannah Charles (0000-0002-3229-6198), Katie Thorley (0000-0003-4322-2909),
- 4 Charlie Turner, Kirsty F. Bennet (0000-0002-4730-4779), Nick Andrews, Marta Bertran,
- 5 Sema Mandal (0000-0003-3379-3118), Gayatri Amirthalingam, Mary E. Ramsay, Hamish
- 6 Mohammed (0000-0002-2060-7286), Katy Sinka (0000-0001-8596-0649)
- 7 **Affiliation**: UK Health Security Agency, London, UK
- 8 Corresponding author: Hannah Charles, UK Health Security Agency, 61 Colindale Avenue,
- 9 London, NW9 5EQ, UK; email: hannah.charles@ukhsa.gov.uk
- 11 Keywords: mpox, surveillance, epidemiology, men who have sex with men, GBMSM,
- vaccine effectiveness

Abstract

10

13

14

- 15 England, like other countries that experienced a large outbreak of emergent mpox in 2022,
- continued to record cases during 2023 at a low but steady frequency. Comprehensive
- 17 national surveillance shows that cases continue to occur primarily among gay, bisexual and
- other men who have sex with men mostly in London. Of 137 cases in 2023, around half were
- 19 acquired overseas, half were vaccinated, and one case of reinfection was reported. Eleven
- 20 people required hospital care. High vaccination uptake, during 2022, has provided good
- 21 coverage of those at higher risk of mpox. Using the screening method, vaccine effectiveness
- of one dose was estimated at 84%. None of the vaccinated cases in 2023 were hospitalised.
- **Ethical statement**: This analysis was undertaken for health protection purposes under
- 25 permissions granted to UKHSA to collect and process confidential patient data under
- 26 Regulation 3 of The Health Service (Control of Patient Information) Regulations 2020 and
- 27 Section 251 of the National Health Service Act 2006.
- **Funding statement**: No external funding was received for this work.
- 29 **Acknowledgements**: We would like to thank NHS England for their collection and sharing
- 30 of vaccination data for the mpox vaccination programme and sexual health services for
- 31 delivering the vaccines. We would also like to thank the UKHSA Health Protection Teams
- for collecting epidemiological information during public health management of cases.
- 33 **Conflict of interest**: None
- 34 **Authors' contributions**: HC led the epidemiological analysis and drafted the manuscript.
- 35 The epidemiological data analysis was validated by KT and KFB. NA led the vaccine

37

38

39

40

41

42

43

44

45

46

47

48 49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

effectiveness analysis. All co-authors contributed to interpretation of the findings and to revision of the manuscript. **Introduction** In May 2022, an international outbreak of mpox was identified, primarily affecting highly interconnected sexual networks of gay, bisexual and other men who have sex with men (GBMSM). In England, the number of mpox cases peaked in mid-July 2022 at 350 cases per week (1), and then declined to fewer than six cases per week from November onwards (2). From June 2022, the Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN) vaccine was offered to GBMSM in England who were assessed as being at higher risk of mpox infection, including those with a recent history of multiple partners, participating in group sex or attending sex-on-premises venues (3), with the estimated vaccine effectiveness of one dose being 78% (4). Although the number of cases declined, mpox cases continued to be reported throughout 2023. Surveillance has continued to detect changes in the epidemiology and record risk factors that contribute to the ongoing occurrence of new mpox cases. This analysis summarises the epidemiology of post-peak mpox cases in 2023 in England (01 January to 31 December), describes case characteristics including vaccination status, investigates if characteristics varied to those from the peak of the outbreak, and estimates the effectiveness of vaccination to protect against symptomatic disease. Materials and Methods Records of confirmed and highly probable mpox diagnoses reported between 01 January and 31 December 2023 were extracted from the UK Health Security Agency (UKHSA) Second Generation Surveillance System (SGSS) and deduplicated using specimen and patient identifiers. A confirmed case was defined as a positive monkeypox virus-specific polymerase chain reaction (PCR) and a highly probable case as a positive Orthopoxvirus PCR (5). SGSS receives positive test results from all diagnostic laboratories in England (6). Given the initial status of mpox as a high consequence infectious disease (HCID) and ongoing status as a statutory notifiable disease (7), in addition to the World Health Organization (WHO) classifying the 2022 outbreak as a Public Health Emergency of International Concern (PHEIC) (8), the reporting of mpox diagnoses to SGSS is very likely to be complete.

Additional epidemiological and behavioural information was collected by UKHSA's local

68 Health Protection Teams. Aggregate data on mpox vaccinations administered in 2022 and 69 2023 were provided by National Health Service (NHS) England. Overall vaccine 70 effectiveness was estimated using the screening method (9). Difference between one dose 71 and two dose vaccine effectiveness estimates were tested by a chi-squared test at a 5% 72 significance level. 73 74 Results 75 There were 137 mpox cases in the period between 01 January and 31 December 2023, 135 76 were confirmed cases and two were highly probable. Following an initial period of low-level 77 reporting, with nine cases in total between January and March (Week 1 to Week 13) 2023, 78 there was an increase in the frequency of cases, with a further 128 cases between April and 79 the end of December (Week 17 to Week 52) (Figure 1). Consistent with the outbreak overall, 80 of the 137 mpox cases in 2023, the majority (105 out of 137; 77%) were resident in London; 81 the remaining 32 cases were reported from the East Midlands, South East, Yorkshire and 82 Humber, East of England, North West and South West of England. 83 Most cases identified as GBMSM (107 out of 137; 78%), an additional 21 cases were adult 84 men without recorded information on sexual orientation and for this analysis of cases were 85 assumed to be part of the 2022-23 global mpox outbreak, totalling 128 (out of 137; 93%). 86 Eight cases were not considered to be part of this outbreak given information linking their 87 infection to an mpox endemic country, these were sporadic cases distributed across the time 88 period and consisted of heterosexual individuals and children. There was one further adult 89 case where neither gender nor sexual orientation was reported. 90 Of the 137 cases in 2023, 64 individuals (47%) reported they did not travel outside the United 91 Kingdom (UK) in the 21 days prior to symptom onset, indicating that they likely acquired 92 mpox in the UK; 57 (89%) of these individuals identified as GBMSM (Table 1). 93 Fifty-three individuals (39%) reported travel outside the UK, and of these, 43 (81%) 94 identified as GBMSM and reported travelling to countries in Europe, the Middle East, Asia 95 Pacific and North America. 96 Over half of cases in 2023 associated with the 2022-23 global mpox outbreak were HIV

negative (69 out of 128; 54%), of whom most (51 out of 69; 74%) were taking HIV pre-

exposure prophylaxis (PrEP). Thirty-nine individuals (39 out of 128; 30%) reported attending

97

an event involving sexual contact with multiple partners and 24 individuals (19%) were diagnosed with a concurrent STI. One individual reported also having a previous mpox diagnosis in 2022 (Table 2). Of cases associated with the 2022-23 global mpox outbreak, 52 (49%) of the 106 cases with known vaccination status were fully or partially vaccinated, of whom one case reported three doses, 29 cases received two doses and 20 cases received one dose, and 2 did not report the number of doses. Among these vaccinated cases, 20 (38%) reported attending an event involving sexual contact with multiple partners and were therefore likely to have been at higher risk of exposure to mpox. Eleven individuals were admitted to hospital due to their mpox infection (9%), nine were unvaccinated and two had unknown vaccination status. Overall vaccine effectiveness Between July 2022 and December 2023, 77,543 GBMSM in England were vaccinated against mpox; 32,983 individuals with one dose and 44,560 with two. Based on an estimated eligible GBMSM denominator of 89,240 as used previously (4) this gives a coverage estimate at the end of December 2023 of 37.0% for one dose and 49.9% for two doses (86.9% one or two doses). Most vaccines had been given by March 2023 (91.0% of first doses and 75.7% of second doses). Vaccine effectiveness was calculated using the screening method, as previously described (4). For the primary analysis, the eligible GBMSM denominator was taken to be 89,240 and 20% higher at 107,088 in a sensitivity analysis, similar to previous analyses (4). For the calculation of vaccine effectiveness, the proportion of GBMSM vaccinated was estimated based on matching each case to the one and two dose coverage at the time two weeks before individuals became a case, then averaging this matched coverage across cases. For the 22 cases where vaccination status was unknown, it was assumed that these would be distributed among those with 0, 1 and 2 doses in the same ratio as the observed ratio for these groups, to give a corrected value. Vaccine effectiveness of a single dose was estimated at 84% (Table 3) - comparable to the previous estimate of 78% (4). The vaccine effectiveness of two doses was similar to one dose, at 80% (p=0.40). The overall vaccine effectiveness of one or two doses was 82%.

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

131

132133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

None of the vaccinated cases in 2023 were hospitalised, compared to eleven among those unvaccinated (or where vaccination status was not known). The sensitivity analysis resulted in vaccine effectiveness estimates which were markedly lower, demonstrating that the method is affected by assumptions of the size of the GBMSM population. Discussion The very low case numbers at the start of the 2023 were initially interpreted as the final few cases in the tail of the outbreak from 2022 (1). However, like other countries where the 2022 outbreak had been substantial, cases continued to occur steadily throughout the year with an even split of imported infections and community transmission. The demographic and behavioural characteristics of mpox cases in 2023 remained similar to the peak of the outbreak in 2022 (10-12) and indicate that mpox continues to circulate predominately within interconnected sexual networks of GBMSM. Nearly half of the cases in England in 2023 had been vaccinated and there were more cases among those who had received two doses of MVA-BN vaccine, compared to one dose. The vaccine effectiveness, influenced by the size of the GBMSM population, was similar for one dose and two doses, with the point estimate a little higher for one dose. Considering that first doses will have been given longer ago than second doses and that two dose would be expected to confer more protection the similar VE is counter intuitive. The similar VE may reflect differences in risk behaviour in those who came forward for a second dose of vaccine as they may also be more likely to come into contact with the monkeypox virus. This phenomenon of risk compensation has been suggested with other emerging infectious diseases such as COVID-19, particularly if behaviour modification associated with vaccination status occurs (13)(14). Increased awareness of the effectiveness of the MVA-BN vaccine and associated reduction in fear of mpox since the rollout of the vaccination programme may have also played a part. Critically, the finding that there were no hospitalised cases in 2023 among vaccinated individuals provides assurance that the MVA-BN vaccine protects against severe disease, which is corroborated by a global case series

which found that illness among vaccinated individuals was less severe (15), and recent data

160

161

164

165

166

167

168

169

171

174

175

176

177

178 179

181

183

184

185

186 187

189

191 192

- GOV.UK (www.gov.uk)

from France (16). 162 The picture seen in England is consistent with reports from other high-income countries with 163 outbreaks predominantly among GBMSM - in March 2023, reports of a cluster of mpox in France, included more vaccinated than unvaccinated individuals and in May 2023 the Chicago Department of Public Health noted that the majority of the cases reported since mid-April were among men who had received two doses of MVA-BN vaccine (17), yet a higher number of first doses had been given compared to second doses overall (18). The self-reported reinfection in 2023 follows a previous case reported from 2022 (19). This finding, alongside the observed vaccine breakthrough infections, contributes to the emerging 170 understanding of natural and vaccine induced immunity to mpox. Although the attending sexual health clinic verified that this individual had a positive mpox test in 2022 and another 172 in 2023, it should be acknowledged that a lack of sequencing data cannot rule out persistent 173 infection. The 2023 overall experience in England was of continued low level community transmission among GBMSM, as well as imported infections, which looks set to continue. With over 20 countries continuing to report mpox cases in December 2023 and the WHO assessment that the overall global risk for men who have sex with men remains moderate (20), a forecast long tail to the outbreak is likely before elimination can be achieved. This underpins the importance of continuing with active prevention through vaccination and health promotion to 180 those at higher risk, and ongoing surveillance to better understand factors that contribute to continued transmission. 182 References 1. UK Health Security Agency. Monkeypox outbreak: technical briefing #8. 23/09/2022. Accessed 14/02/2024. Available at: Investigation into monkeypox outbreak in England: technical briefing 8 - GOV.UK (www.gov.uk) 2. UK Health Security Agency. Mpox (monkeypox) outbreak: epidemiological overview, 6 July 2023. Accessed 14/02/2024. Available at: Mpox (monkeypox) outbreak: epidemiological 188 overview, 6 July 2023 - GOV.UK (www.gov.uk) 190 3. UK Health Security Agency. Mpox (monkeypox) outbreak: vaccination strategy. 21 June 2022. Accessed 14/02/2024. Available at: Mpox (monkeypox) outbreak: vaccination strategy

- Bertran M, Andrews N, Davison C, Dugbazah B, Boateng J, Lunt R, et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis. 2023 Jul;23(7):828-35.
- UK Health Security Agency. Monkeypox: case definitions. 2022. Accessed 14/02/2024.
 Available at: Mpox (monkeypox): case definitions GOV.UK (www.gov.uk)

- 198 6. UK Health Security Agency. Reporting to UKHSA: a guide for diagnostic laboratories. 2023.
 199 Accessed 14/02/2024. Available at: Reporting to UKHSA: a guide for diagnostic laboratories
 200 (publishing.service.gov.uk)
 - UK Health Security Agency. Notifiable diseases and causative organisms: how to report.
 2024. Accessed 14/02/2024. Available at: Notifiable diseases and causative organisms: how to report GOV.UK (www.gov.uk)
 - 8. World Health Organization. WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. 2022. Accessed 14/02/2024. Available at: Second meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the multi-country outbreak of monkeypox (who.int)
 - 9. Flannery B, Nick Andrews N, Feikin D, Patel MK, Commentary: Estimation of vaccine effectiveness using the screening method, International Journal of Epidemiology, Volume 52, Issue 1, February 2023, Pages 19–21, https://doi.org/10.1093/ije/dyac013
 - 10. Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, et al. Community transmission of monkeypox in the United Kingdom, April to May 2022. Eurosurveillance. 2022;27(22):2200422.
- 11. Vusirikala A, Charles H, Balasegaram S, Macdonald N, Kumar D, Barker-Burnside C, et al.
 Epidemiology of Early Monkeypox Virus Transmission in Sexual Networks of Gay and
 Bisexual Men, England, 2022. Emerg Infect Dis. 2022 Oct;28(10):2082-6.
 - 12. Charles H, Prochazka M, Murray J, Sexual Health Liaison Group U, Soni S, Haddow L, et al. Surveillance of Mpox Cases Attending Sexual Health Services in England (SOMASS): design, implementation and initial findings from the SOMASS data collection tool, 2022. Sex Transm Infect. 2023 May 18.
 - 13. Brewer NT, Cuite CL, Herrington JE, Weinstein ND. Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors? Ann Behav Med. 2007 Aug;34(1):95-9. doi: 10.1007/BF02879925. PMID: 17688401.
 - 14. Buckell, J., Jones, J., Matthews, P.C. *et al.* COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK. *Sci Rep* **13**, 8441 (2023). https://doi.org/10.1038/s41598-023-34244-2
 - 15. Hazra A, Zucker J, Bell E, Flores J, Gordon L, Mitjà O, et al. Mpox in people with past infection or a complete vaccination course: a global case series. Lancet Infect Dis. 2023 Sep 4.
 - 16. Sante Publique France. Monkeypox: update on the situation in France as of March 23, 2023. Accessed 14/02/2024. Available at: Monkeypox: update on the situation in France as of 23 March 2023 | Public Health France (santepubliquefrance.fr)
 - 17. Chicago Health Alert Network. RESURGENCE OF MPOX Provider Update: May 9, 2023. Accessed 14/02/2024. Available at: Alert Detail HAN (chicagohan.org)
- 18. Chicago Department of Public Health. Mpox dashboard. 2023. Accessed 14/02/2024.
 Available at: City of Chicago :: Mpox Dashboard
- 19. Golden J, Harryman L, Crofts M, Muir P, Donati M, Gillett S, Irish C. Case of apparent mpox reinfection. Sex Transm Infect. 2023 Jun;99(4):283-284. doi: 10.1136/sextrans-2022-055736.
 Epub 2023 Jan 27. PMID: 36707246; PMCID: PMC10313946.
- 20. World Health Organization. Multi-country outbreak of mpox, External situation report#31 –
 22 December 2023. Accessed 14/02/2024. Available at: Multi-country outbreak of mpox,
 External situation report#31 22 December 2023 (who.int)

Table 1: Exposure classification of confirmed and highly probable mpox cases, by

gender and sexual orientation, England, 01 January to 31 December 2023

	Cases presumed acquired in the UK	Cases presumed acquired outside the UK	Country of acquisition unknown
Gender and sexual orientation	n (%)*	n (%)*	n (%)*
GBMSM	57 (89)	43 (81)	6 (30)
Non-GBMSM or unknown	7 (11)	10 (19)	14 (70)
Total	64	53	20

GBMSM: Gay, bisexual and other men who have sex with men

^{*} Percentages are column percentages

Table 2: Characteristics and risk factors of confirmed and highly probable mpox cases

associated with the 2022-23 global mpox outbreak, England, 01 January to 31

December 2023

	n (%)	
HIV status		
Living with HIV	13 (10)	
HIV negative	69 (54)	
Taking HIV PrEP*	51 (74)	
Not taking PrEP*	18 (26)	
Unknown	46 (36)	
Vaccination status		
Vaccinated – ≥2 doses □	30 (23)	
Vaccinated – 1 dose	20 (16)	
Vaccinated – number of doses unknown	2 (2)	
Unvaccinated	54 (42)	
Unknown	22 (17)	
Hospital admission		
Yes	11 (9)	
No/unknown	117 (91)	
Reporting attending events involving		
multiple sexual partners		
Yes	39 (30)	
No/unknown	98 (70)	
Concurrent STI		
Yes	24 (19)	
No/unknown	104 (81)	
Previous mpox diagnosis		
Yes	1 (1)	
No	64 (50)	
Unknown	63 (49)	

266 HIV PrEP: HIV pre-exposure prophylaxis

Unless otherwise stated, the denominator is 128

^{*} Denominator for percentage calculations is HIV negative individuals


- Table 3: Vaccination status of mpox cases during 2023 used to estimate vaccine
- 277 effectiveness of one dose, two doses and one or two doses of Modified Vaccinia Ankara –
- 278 Bavarian Nordic (MVA-BN) vaccine using the screening method

283

Doses	2023 Cases	Corrected Cases*	PCV	PPV	PPV	VE (95% CI)	VE (95% CI)
					(sensitivity**)		(sensitivity**)
0	54	65.4	52%	16%	30%		
1	20	24.2	19%	38%	32%	84% (74-91)	65% (42-79)
2	30	36.4	29%	45%	38%	80% (69-83)	56% (31-72)
Unknown status	22						
1 or 2	50	60.6	48%	84%	70%	82% (74-88)	60% (41-73)
Total	126	126					

- 279 PCV = proportion of cases with the given number of doses; PPV = proportion of the
- population with the given number of doses obtained by matching each case to the population
- uptake 14 days prior to onset and averaging this across cases; VE = vaccine effectiveness.
 - * 22 cases with unknown vaccination status distributed among 0, 1 and 2 doses. ** based on the higher estimated GBMSM denominator (107,088)

Figure 1. Confirmed and highly probable mpox cases by week of specimen date in England, 01 January to 31 December 2023



Week number (2023)